# Therapy Classification Summary

## Overview

This document summarizes the implementation of therapy approval status classification for clinical trial treatment arms.

## Files Created

1. **`resources/therapy_approval_status.yaml`** - YAML configuration file with therapy categorization
2. **`src/domain/therapy_classifier_config.py`** - Python configuration module (no external dependencies)
3. **`src/domain/therapy_classifier.py`** - Therapy classification module
4. **`validate_therapy_classification.py`** - Validation script

## Classification Results

Based on analysis of 1,104 trials with 1,632 treatment arms:

- **Approved/Standard of Care**: 696 arms (42.6%)
- **Investigational**: 177 arms (10.8%)
- **Control/Comparator**: 84 arms (5.1%)
- **Unknown**: 675 arms (41.4%)

## Approved Therapies

### Immune Checkpoint Inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Ipilimumab (Yervoy)
- Cemiplimab (Libtayo)
- Avelumab (Bavencio)
- Atezolizumab (Tecentriq)

### Targeted Therapies
- Dabrafenib + Trametinib
- Vemurafenib + Cobimetinib
- Encorafenib + Binimetinib

### Chemotherapy
- Dacarbazine
- Temozolomide
- Fotemustine

### Local Therapies
- T-VEC (Talimogene laherparepvec)
- Imiquimod
- Melphalan

## Investigational Therapies

### Novel Checkpoint Inhibitors
- Relatlimab (Anti-LAG-3)
- Fianlimab (Anti-LAG-3)
- Tiragolumab (Anti-TIGIT)
- Vibostolimab (Anti-TIGIT)
- Quavonlimab (Qmab, Anti-CTLA-4)
- Gotistobart (ONC-392, Anti-CTLA-4)
- Domatinostat (HDAC inhibitor)

### Cell Therapies
- Lifileucel (LN-144, TILs)
- OBX-115 (Engineered TILs)
- Tebentafusp (IMCgp100)
- SCIB1
- PRAME TCR/IL-15 NK Cells

### Vaccines
- mRNA-4157 (V940)
- Seviprotimut-L
- TLPLDC
- IFx-Hu2.0

### Oncolytic Viruses
- TILT-123
- RP1 (Vusolimogene oderparepvec)
- Daromun (L19IL2 + L19TNF)
- PV-10

### Small Molecules
- Lenvatinib
- Darovasertib (IDE196)
- Sitravatinib
- Ripretinib (DCC-2618)
- Tunlametinib (HL-085)
- Navtemadlin (KRT-232)

### Radiopharmaceuticals
- 212Pb-VMT01
- 225Ac-MTI-201

## Usage

### Basic Classification

```python
from src.domain.therapy_classifier import TherapyClassifier, TherapyStatus

classifier = TherapyClassifier()

# Classify an arm
status = classifier.classify_arm(
    arm_name="Pembrolizumab",
    generic_name="pembrolizumab",
    title="Phase 3 study of Pembrolizumab"
)

print(status)  # TherapyStatus.APPROVED
```

### Get Therapy Details

```python
details = classifier.get_therapy_details("Pembrolizumab")
# Returns dict with status, category, indications, etc.
```

## Integration with API

To add approval status to the API response, you can extend the `ArmData` model:

```python
class ArmData(BaseModel):
    arm_name: str
    generic_name: str
    approval_status: Optional[str] = None  # "approved", "investigational", "control", "unknown"
```

Then classify arms when building the response:

```python
classifier = TherapyClassifier()
for arm in arms:
    status = classifier.classify_arm(arm.arm_name, arm.generic_name, trial.title)
    arm.approval_status = status.value
```

## Notes

- The "Unknown" category (41.4%) includes arms with:
  - Abbreviated names (e.g., "COMBO450", "ENCO300")
  - Combinations not in the lookup tables
  - Novel agents not yet categorized
  - Generic descriptions (e.g., "Anti-PD1 Antibody Monotherapy")

- The classification can be improved by:
  - Adding more therapy names and aliases
  - Handling abbreviated names
  - Improving combination therapy detection
  - Adding context from trial phase/status

## Next Steps

1. **Enhance Classification**: Add more therapy names, handle abbreviations
2. **API Integration**: Add approval_status field to API responses
3. **Frontend Integration**: Display approval status in UI with filters
4. **Regular Updates**: Keep therapy list updated as new approvals occur

